Skip to main content

Table 3 Evaluation of pre-treatment and on-treatment annualised relapse ratio and EDSS according to treatment group

From: Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease

Treatment group Treated ≥ 6 months at any time, n (%) Eligible for analysis, n (%) FU before treatment (years), median (range) FU under treatment (years), median (range) ARR pre/on-treatment, mean (SD) Freedom of relapse on-treatment
n (%)
p value
ARR pre/on-treatment
EDSS pre/end of treatment, mean (SD) Freedom of EDSS progression, n (%) p value
EDSS pre/end-treatment
Type I IS AZT 19/66 (28.8) 11/19 (57.9) 2.4 (0.6–7.6) 2.1 (0.5–12.6) 1.05 (1.20)/ 0.43 (0.79) 6 (54.5) 0.041 1.86 (1.30)/ 1.68 (1.19) 11 (100) 0.157
MMF 12/66 (18.2) 11/12 (91.7) 1.7 (0.5–46.4) 1.7 (0.5–6.8) 1.20 (1.11)/ 0.23 (0.60) 8 (72.7) 0.033 2.72 (1.69)/
2.64 (1.76)
11 (100) 0.317
RTX 30/66 (45.5) 26/30 (86.7) 3.3 (0.5–18.33) 1.7 (0.5–4.9) 1.08 (0.98)/
0.43 (0.89)
19 (73.1) 0.012 3.11 (1.83)/
2.58 (1.90)
23 (88.5) 0.096
Type II IS 6/66 (9.1) 5/6 (83.3) 5.2 (2.9–10.3) 2.0 (0.6–3.7) 0.64 (0.45)/
0.65 (0.69)
2 (40) 0.893 3.8 (1.52)/
4.0 (1.45)
1 (20.0) 0.317
Type III IS 8/66 (12.1) 3/8 (37.5)
aMS-DMD 10/66 (6.6) 9/10 (90) 1.95 (0.5–20.1) 3.7 (1.0–14.7) 1.13 (1.38)/
0.49 (0.41)
2 (22.2) 0.374 2.5 (0.90)/
3.17 (2.15)
7 (77.7) 0.188
  1. *Patients treated with type III IS (corticosteroids, n = 2 and intravenous immunoglobulins, n = 1) were not eligible for analysis due to treated number ≤ 5
  2. aAmong the 9 patients with MS-DMD eligible for the analysis, 2 patients were treated with natalizumab, 1 with glatiramer acetate and 6 with interferon
  3. FU follow-up, ARR annualised relapse ratio, SD standard deviation, EDSS Expanded Disability Status Scale, IS immunosuppressants, MS-DMD multiple sclerosis disease-modifying drugs, AZT azathioprine, MMF mycophenolate mophetil, RTX rituximab